Pharmaceutically acceptable salts of psilocin and uses thereof
The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
1. A crystal form of a 1:1 benzoate salt of psilocin having at least four, five, six, or seven peaks at diffraction angle 2θ)(°) 9.4±0.5, 10.9±0.5, 12.3±0.5, 13.3±0.5, 14.5±0.5, 15.3±0.5, 16.3±0.5, 16.4±0.5, 18.2±0.5, 18.9±0.5, 19.3±0.5, 19.7±0.5, 20.0±0.5, 20.8±0.5, 21.3±0.5, 21.9±0.5, 22.6±0.5, 22.9±0.5, 23.8±0.5, 24.1±0.5, 24.9±0.5, 25.6±0.5, 26.0±0.5, 26.3±0.5, 26.5±0.5, 26.9±0.5, 27.5±0.5, and 28.5±0.5 (BEN Pattern 1) as measured by X-ray powder diffractometry.
2. A pharmaceutical composition comprising a crystal form of claim 1 and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is stored in an amber bottle.
4. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition of claim 2 in an amount sufficient to treat the disease or condition, wherein the disease or condition is lung inflammation, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, septicemia, chronic obstructive pulmonary disease (COPD), stroke, a traumatic brain injury, a spinal cord injury, chronic pain, depression, anxiety, addiction, post-traumatic stress disorder, an eating disorder, compulsive behavior, Huntington's disease, or Parkinson's disease.
5. The method of claim 4 , wherein the disease or condition is lung inflammation, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, and/or septicemia.
6. The method of claim 4 , wherein the disease or condition is chronic obstructive pulmonary disease (COPD).
7. The method of claim 4 , wherein the disease or a condition is a stroke, a traumatic brain injury, or a spinal cord injury.
8. The method of claim 4 , wherein the disease or condition is chronic pain.
9. The method of claim 8 , wherein the chronic pain results from post-operative pain, tension headaches, chronic lower back pain, fibromyalgia, nephropathy, multiple sclerosis, shingles, complex regional pain syndrome, cephalic pain, or sciatica.
10. The method of claim 9 , wherein the chronic pain condition results from trigeminal autonomic cephalalgia.
11. The method of claim 10 , wherein the trigeminal autonomic cephalalgia is selected from the group consisting of episodic and chronic cluster headache (CH), episodic and chronic paroxysmal hemicrania (PH), and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT).
12. The method of claim 11 , wherein the trigeminal autonomic cephalalgia is episodic or chronic CH.
13. The method of claim 4 , wherein the disease or condition is depression, anxiety, addiction, post-traumatic stress disorder, an eating disorder, or compulsive behavior.
14. The method of claim 13 , wherein the disease or condition is depression.
15. The method of claim 4 , wherein the disease or condition is anxiety.
16. The method of claim 4 , wherein the disease or condition is Huntington's disease or Parkinson's disease.